Form 4: Heron Therapeutics Director Acquires Shares and Options in Recent Transaction

Director Sharmila Dissanaike acquired 17,950 restricted stock units and 35,900 stock options in Heron Therapeutics, according to a recent SEC filing.

Summary

• Sharmila Dissanaike, a director at Heron Therapeutics, acquired 17,950 restricted stock units and 35,900 stock options on January 30, 2025.
• The restricted stock units vest fully on January 30, 2026, and each unit represents the right to receive one share of common stock.
• The stock options vest in 12 equal monthly installments starting one month after the grant date and expire on January 30, 2035.
• The exercise price for the stock options is $1.73 per share.
• Following these transactions, Ms. Dissanaike directly owns 87,180 shares of Heron Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the acquisition of shares and options by a director is generally viewed positively as it indicates confidence in the company's future.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedules and exercise prices are typical for such grants, aligning with industry norms for incentivizing long-term performance and retention.
• Comparable companies such as BioMarin Pharmaceutical and Regeneron Pharmaceuticals also use similar equity-based compensation strategies for their directors.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's prospects.

Key Dates

Keywords

Heron Therapeutics, Director, Stock Options, Restricted Stock Units, SEC Form 4, Insider Trading, Equity Compensation